Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Genfit (Group)

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (“RESOLVE-IT”) in nonalcoholic steatohepatitis (“NASH”), considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (“PBC”), a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT – ISIN: FR0004163111). *

 

Period Start 1999-01-01 established
Products Industry elafibranor (GFT505)
  Industry 2 drug development
Person Person Mouney, Jean-François (Genfit 201909– Board Chairman before 1999–201909 CEO + Co-Founder)
     
Region Region Loos (Loos-lez-Lille)
  Country France
  Street 885 Avenue Eugène Avinée
Parc Eurosanté
  City 59120 Loos
  Tel +33-3-2016-4000
    Address record changed: 2019-03-06
     
Basic data Employees D: 101 to 500 (2016-12-31)
  Currency EUR
  Annual sales 6,783,000 (income, total, consolidated (2016) 2016-12-31)
  Profit -33,667,000 (2016-12-31)
  Cash 152,277,000 (2016-12-31)
     
    * Document for �About Section�: Genfit S.A.. (2/27/19). "Press Release: Genfit Files Registration Statement for Proposed Initial Public Offering in the United States". Lille & Cambridge, MA.
     
   
Record changed: 2019-06-03

Advertisement

Picture [iito] No Tracking 650x80px

More documents for Genfit (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top